Osteoporosis
Conditions
Interventions
The participants will be randomized to two treatment groups, in a cross-over
design, with an one week wash-out period:
Group 1 will first receive subcutaneous Teriparatide 20*g daily (12 weeks) and
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Male sex 50-80 years Recently diagnosed primary osteoporosis Testosterone within reference range
Exclusion criteria
Exclusion criteria: Contraindication to parathyroid hormone therapy: hypersensitivity to the active substrate or to any of the excipients, pre-existing hypercalcaemia, hepatic- or renal insufficiency, metabolic bone diseases other than primary osteoporosis or glucocorticoid-induced osteoporosis, unexplained elevations of alkaline phosphatase, prior external beam or implant radiation therapy to the skeleton, patients with skeletal malignancies or bone metastases ;Any medication or disease influencing bone turnover Diabetes mellitus Hypogonadism Inability to give informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| * undercarboxylated osteocalcin * testosterone concentrations * glucose tolerance determined by an oral glucose tolerance test * insulin sensitivity determined by a hyperinsulinemic euglycemic clamp * changes in body composition by a whole-body DXA scan All patients will be studied at baseline and after 6 and 12 weeks of intervention. Patients will serve as their own controls. | — |
Countries
Netherlands
Outcome results
None listed